ClinicalTrials.gg
RecruitingNCT03870802MACSSIUpdated Jan 25, 2024

MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire)

An observational study in Breast Cancer, sponsored by Centre Leon Berard. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Centre Leon Berard · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Breast Neoplasms by Centre Leon Berard — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Centre Leon Berard.

Started
2021
with 1 other
Observational
7 of 23
4 open now
Registered
16th of 23
by date

Among the 23 studies in Breast Neoplasms by Centre Leon Berard, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 23 studies in Breast Neoplasms by Centre Leon Berard are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Breast Neoplasms by Centre Leon Berard, or all of them as a file.
02

Study summary

Monocentric, observational and prospective study in adult women having an early-stage breast cancer without genetic risk.

The main objective is to characterize quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland in women:

  • With a moderate risk of breast cancer progression (women with an early "Luminal A" tumor) = Group A.
  • With a high risk of breast cancer progression (women with an early "Luminal B" or basal tumor) = Group B.
Read the detailed description

Breast cancer is one of the most frequent and the second cause of mortality for women in the world. Breast is a complex organ which has several changes (puberty, pregnancy and menopause). These modifications are controlled by numerous signals as those transmitted by the oestrogens. They are possible through the presence of stem cells in the mammary gland which are able to reply to these signals and can be the target of alterations leading to cancer cells occurence. Breast tumors are composed of complex entities of different kinds of cancer and normal cells which constitute the tumor micro-environment including the immune system cells. This micro-environment transmits a lot of signals to cancer cells and particularly stem cells which can contribute to their survival, the tumor progression and interfere with the treatments efficacy.

The detection of the major deregulation of BMP2 synthesis by mammary micro-environment cells may be a reliable and early biomarker of carcinogens exposure and an indicator of a high risk of developing a luminal type breast cancer.

The immune micro-environment, which has an impact on solid cancer patients' survival, should be taken into consideration for new therapeutic strategies.

Some infiltrating tumour immune cells, as macrophages (TAM) or regulating T and B cells, have shown their key role in tumour escape and metastases apparition. It is relevant to associate the evaluation of immune infiltrate to the breast stem cells in early stage tumours since the literature suggests a functional interaction of these two cellular compartments, particularly in the glioblastoma and the prostate cancer. It seems that mammary stem cells are a major element in the comprehension of breast carcinogenesis but also in the possibilities of repairing the mammary tissue controlling the mammary carcinogenesis.

It is fundamental to clarify the role of stem cells and immunity. Our hypothesis is that breast stem cells are altered in women having a high risk of cancer progression. They would be responsible for a reduced activity of cellular repair and/or contribute to tumour development.

MACSSI project consists in isolating, quantifying and characterizing the breast stem cells and the isolated immune cells of samples obtained for the prophylactic mastectomy in women presenting different tumour progression risks.

The results will be compared to normal samples already collected in women who had a breast reduction.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • Stem cells
  • Immune cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Adult women having an early-stage breast cancer without genetic risk requiring a breast surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patient requiring a breast surgery (total mastectomy) of an early stage tumour classified as :

    • Luminal A (Arm A) : Patients with a moderate risk of breast cancer progression or,
    • Luminal B or Basal (Arm B) : Patients with a high risk of breast cancer progression
  • Systemic treatment not initiated
  • Breast cup size ≥ C
  • Informed and signed consent.

Exclusion criteria

Exclusion Criteria:

  • chemotherapy or hormonotherapy
  • History of breast irradiation
  • Pregnant or breastfeeding woman
  • Patient under tutorship or curatorship
  • Patient who underwent a lumpectomy with a level-2 oncoplastic surgery (ex: breast reduction with an inverted-T remodeling)
  • Any other prior anti-tumor treatment
  • Other medical pathology which may interfere with the biologic evaluation, especially chronic auto-immune diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherCharacterization of breast stem & immune system cells infiltrated in the mammary gland

    Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.

06

What researchers measure

Primary outcomes

  1. To characterise quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland according to the risk of breast cancer progression (group A and B)

    Rate of stem and immune cells and phenotype analysis

    Time frame: Within one month after inclusion (date of surgery)

Secondary outcomes

  1. Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B

    Functional test: mammosphere

    Time frame: Within one month after inclusion (date of surgery)

  2. Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B

    Functional test: TDLU

    Time frame: Within one month after inclusion (date of surgery)

  3. Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B

    Functional test: E-CFC - FACS

    Time frame: Within one month after inclusion (date of surgery)

  4. Determination of the stem cells role in the cellular regulation and repair activity

    Functional tests

    Time frame: Within one month after inclusion (date of surgery)

  5. Determination of the efficacy of the immune systems cells found in the samples in the early stage of breast tumorigenesis

    FACS

    Time frame: Within one month after inclusion (date of surgery)

  6. Evaluation of the role of breast stem and immune cells in the early stage development of a breast cancer: risk or protective factor ?

    Functional tests: mammosphere, TDLU, E-CFC - FACS

    Time frame: Within one month after inclusion (date of surgery)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2024, 36 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 36 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2018
First posted
Mar 12, 2019
StartActual
Feb 22, 2021
Primary completionEst.
Feb 22, 2024
CompletionEst.
Nov 15, 2024
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03870802
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Mar 12, 2019
Start date
Feb 22, 2021
Primary completion
Feb 22, 2024 (estimated)
Completion
Nov 15, 2024 (estimated)
Last update
Jan 25, 2024

Study contacts

DELAY Emmanuel, MD
Contact
emmanuel.delay@lyon.unicancer.fr
+33 4.78.78.51.29
DAMMACCO Delia, MD
Contact
maria-adele.dammacco@lyon.unicancer.fr
+33 4.78.78.27.76
DELAY Emmanuel, MD
principal investigator · Centre Leon Berard

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion